Document:

Exhibit 10.1

    

     

    

    
      FORM OF EXECUTION VERSION

      
        

        

      

      
        FIRST AMENDMENT TO THE SUBSCRIPTION AGREEMENT

        

        

        [___________], 2019

         

        

      

      
        THIS FIRST AMENDMENT TO THE SUBSCRIPTION AGREEMENT (this “Agreement”), made as of [___________], 2019, is by and among Trinity Sub Inc., a Maryland corporation (the “Company”), and [___________],
          a [___________] (the “Subscriber”).

      

      
        

        

      

      
        The Subscription Agreement, dated as of August 9, 2019 (the “Subscription Agreement”), shall be amended as set forth below.  All capitalized terms used but not defined herein shall have the
          meanings set forth in the Subscription Agreement.

      

      
         

        

      

      
        WHEREAS, pursuant to the Subscription Agreement, the Company has, among other things, agreed to issue to the Subscriber concurrently with the Closing a number of warrants equal to the number of
          Initial Shares, on the terms and subject to the conditions contained therein;

      

      
        

        

      

      
        WHEREAS, as a condition to the closing of the Transaction, holders of at least 65% of those certain 34,500,000 outstanding public warrants of the SPAC (the “Public Warrants”), issued pursuant to
          that certain Warrant Agreement (as defined in the Merger Agreement), must approve and consent to the Warrant Amendment Proposal (as defined in the Merger Agreement), whereby the Warrant Agreement will be amended to remove the anti-dilution
          provisions contained in Section 4.1.2 of the Warrant Agreement relating to the payment of cash dividends, as set forth in Exhibit A;

      

      
        

        

      

      
        WHEREAS, to induce holders of the Public Warrants to approve and consent to the Warrant Amendment Proposal, the SPAC intends to seek to also amend the Warrant Agreement to provide for a cash
          payment of $1.60, payable in respect of each Public Warrant (the “Warrant Cash Payment”), and to reduce the number of shares of Common Stock for which each Public Warrant will be exercisable, in each case contingent upon the consummation of the
          Transaction; and

      

      
        

        

      

      
        WHEREAS, the parties desire to amend the terms of the Subscription Agreement to clarify (i) the exercise mechanics of the warrants to be issued to the Subscriber by the Company and (ii) that the
          Warrant Cash Payment will be paid to Subscriber in respect of the warrants to be issued to the Subscriber by the Company.

      

      
         

        

      

      
        NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending
          to be legally bound hereby, the parties hereto agree as follows:

      

      
         

        

        1.     Amendment of Subscription Agreement.  The Company and the Subscriber hereby amend the Subscription Agreement as provided in this Section 1,
          effective as of the date first set forth above.

      

      
         

        

      

      
        1.1 Section 3.c.iii of the Subscription Agreement is hereby deleted and replaced in its entirety with the following:

         

        

      

      
        “iii. the Company shall have issued to the undersigned, concurrently with the Closing, a number of warrants equal to the number of the Initial Shares subscribed by the
          undersigned (and not including any number of Optional Shares for which the undersigned has the right to subscribe) (the “Warrants”), with each Warrant entitling the holder thereof to purchase the number of shares of Common Stock at the
          same exercise price as provided in, and otherwise on substantially the same terms as, those certain 34,500,000 outstanding public warrants (“Public Warrants”) issued by the SPAC pursuant to that certain Warrant Agreement (as defined in the
          Merger Agreement), as amended and  in effect as of the consummation of the Transaction (other than such differences as may be attributable to the fact that the Warrants are being issued by the Company to the undersigned in one or more
          transactions exempt from registration under the Securities Act of 1933, as amended);”

         

        

      

      
        
          

      

      
        
          FORM OF EXECUTION VERSION

           

          

        

        1.2 Section 3.c.vi of the Subscription Agreement is hereby deleted and replaced in its entirety with the following:

         

        

      

      
        “vi. the undersigned shall have received payment from the Company of a fee (the “Warrant Equalization Fee”), payable in cash concurrently with the Closing, in an amount
          equal to (A) the number of the Warrants acquired by the undersigned pursuant to this Agreement multiplied by (B) the amount of the cash distribution payable per each Public Warrant pursuant to Section 7.4.3 of the Warrant Agreement, as amended
          and in effect as of the consummation of the Transaction (provided, however, that the Warrant Equalization Fee shall in no event be less than $0.30 per Warrant acquired by the undersigned pursuant to this Agreement);”

         

        

      

      
        2.     Miscellaneous Provisions.

      

      
         

        

      

      
        2.1 Effectiveness of Subscription Agreement.  All provisions of the Subscription Agreement, except as expressly amended and modified
          by this Agreement, shall remain in full force and effect.

         

        

      

      
        2.2  Applicable Law; Submission to Jurisdiction; Waiver of Jury Trial.

         

          

      

      
        2.2.1.      THIS AGREEMENT AND ANY CLAIMS OR CAUSES OF ACTION HEREUNDER BASED UPON, ARISING OUT OF OR RELATED TO THIS AGREEMENT (WHETHER BASED ON LAW, IN EQUITY, IN CONTRACT,
          IN TORT OR ANY OTHER THEORY) OR THE NEGOTIATION, EXECUTION, PERFORMANCE OR ENFORCEMENT OF THIS AGREEMENT, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF
          LAWS THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

         

        

        2.2.2.      EACH PARTY HERETO IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, THE SUPREME COURT OF
          THE STATE OF NEW YORK AND THE FEDERAL COURTS OF THE UNITED STATES OF AMERICA LOCATED IN THE STATE OF NEW YORK SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS AGREEMENT AND THE DOCUMENTS REFERRED TO IN THIS
          AGREEMENT AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVES, AND AGREES NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT
          THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE
          PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY SUCH A NEW YORK STATE OR FEDERAL COURT.  THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER
          THE PERSON OF SUCH PARTIES AND OVER THE SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR PROCEEDING TO THE ADDRESS AT THE SIGNATURE PAGE HEREIN OR IN SUCH OTHER MANNER AS MAY
          BE PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE THEREOF.

         

        

      

      
        2.2.3.      EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY IS LIKELY TO INVOLVE
          COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
          AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.  EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
          EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY AND (IV) SUCH PARTY HAS BEEN INDUCED TO
          ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 2.2.

        

        

        
          
            

        

      

      
        
          FORM OF EXECUTION VERSION

           

          

        

        2.3 Counterparts.  This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts
          shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

      

      
         

        

      

      
        2.4 Effect of Headings.  The section headings herein are for convenience only and are not part of this Agreement and shall not affect
          the interpretation thereof.

      

      
         

        

      

      
        2.5 Severability.  If any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality or
          enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby and shall continue in full force and effect.

      

      
         

        

      

      
        2.6 Entire Agreement.  The Subscription Agreement, as modified by this Agreement, constitutes the entire understanding of the parties
          and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to the subject matter hereof.

      

      
         

        

      

      
        [Signature page follows]

         

        

        
          
            

        

        FORM OF EXECUTION VERSION

      

      
         

          

        IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.

         

        

      

      	

            	
              TRINITY SUB INC.

            
	

            	

            
	

            	
              By:

            	

            	

            
	

            	

            	
              Name:

            
	

            	

            	
              Title:

            

       

      

      
        [Signature Page to Amendment of Subscription Agreement]

         

        

      

      
        
          

      

      
        FORM OF EXECUTION VERSION

         

        

      

      	

            	
              [___________]

            
	

            	

            	

            
	

            	
              By:

            	

            	

            
	

            	

            	
              Name:

            
	

            	

            	
              Title:

            

      
         

        

        
          [Signature Page to Amendment of Subscription Agreement]

           

          

        

        
          
            

        

      

      
        Exhibit A

        Warrant Amendment Proposal

        

        

        
          The substantive text of the proposed Warrant Amendment is as follows:

        

        
          

          

          

          

        

        
          3.1           Warrant
                  Price.  Each Warrant shall, when countersigned by the Warrant Agent, entitle the Registered Holder thereof, subject to the provisions of such Warrant and of this Agreement, to purchase from the Company the number of shares of Common
                Stock stated therein, at the price of $11.50 per share,, at such price equal to the Exercise Price described in Exhibit A for such Public
                  Warrants and Private Warrants, as applicable (each subject to the adjustments provided in Section 4 hereof and in the last sentence of this Section 3.1. 3.1); provided, however, that a Public Warrant may not be exercised for a fractional share, so that only a multiple of four Public Warrants
                  may be exercised at a given time.  The term “Warrant Price” as used in this Agreement shall mean the price per shareExercise Price (as specified in Exhibit A hereto) at which shares of Common Stock may be purchased at the time a Warrant is
                exercised. The Company in its sole discretion may lower the Warrant Price at any time prior to the Expiration Date (as defined below) for a period of not less than twenty (20) Business Days, provided, that the Company shall provide at least
                twenty (20) days prior written notice of such reduction to Registered Holders of the Warrants and, provided further that any such reduction shall be identical among all of the Warrants.

        

        
          

          

          ****

        

        
          

          

          4.1.2          Extraordinary
                  Dividends. If the Company, at any time while the Warrants are outstanding and unexpired, shall pay a dividend or make a distribution in cash, securities or other assets to the holders of the
                Common Stock on account of such shares of Common Stock (or other shares of the Company’s capital stock into which the Warrants are convertible), other than (a) as described in subsection 4.1.1 above, (b) Ordinary Cash Dividends (as defined below), (cregular monthly, quarterly or other periodic cash dividends or cash distributions, (c) any other
                  cash dividend or distribution required to be paid in order for the Company to qualify or maintain its status as a real estate investment trust within the meaning of the Internal Revenue Code of 1986, as amended, or otherwise avoid the
                  imposition of U.S. federal and state income and excise taxes, so long as the Company qualifies or is seeking to maintain its status as a real estate investment trust at the time of such cash dividend or distribution, (d) to satisfy
                the redemption rights of the holders of the Common Stock in connection with a proposed initial Business Combination, (de) as a result
                of the repurchase of shares of Common Stock by the Company if a proposed Business Combination is presented to the stockholders of the Company for approval, (ef) to satisfy the redemption rights of the holders of Common Stock in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation to modify the
                substance or timing of the Company’s obligation to redeem 100% of the public shares of Common Stock if the Company does not complete the Business Combination within the period set forth in 
                the Company’s amended and restated certificate of incorporation or (fg) in connection with the redemption of public shares of Common
                Stock upon the failure of the Company to complete its initial Business Combination and any subsequent distribution of its assets upon its liquidation (any such non-excluded event being referred to herein as an “Extraordinary Dividend”), then the Warrant Price shall be decreased, effective immediately after the effective date of such Extraordinary Dividend, by the
                amount of cash and/or the fair market value (as determined by the Board, in good faith) of any securities or other assets paid on each share of Common Stock in respect of such Extraordinary Dividend.
                    For purposes of this subsection 4.1.2, “Ordinary Cash Dividends” means any cash
                    dividend or cash distribution which, when combined on a per share basis, with the per share amounts of all other cash dividends and cash distributions paid on the Common Stock during the 365-day period ending on the date of declaration
                    of such dividend or distribution (as adjusted to appropriately reflect any of the events referred to in other subsections of this Section 4 and excluding cash dividends or cash distributions that resulted in an adjustment to the Warrant Price or to the number of shares of Common Stock issuable on exercise of each Warrant) does not
                    exceed $0.50 (being 5% of the offering price of the Units in the Offering).

        

        
          

          

          ****

          

          

          
            
              

          

        

        
          7.4.3          Mandatory Cash Distribution.  Notwithstanding anything contained in this Agreement to the contrary, at the Effective Time (as defined in the Merger
                  Agreement), each Public Warrant issued and outstanding immediately prior to the Effective Time shall, automatically and without any action by the Registered Holder thereof, be entitled to receive a cash distribution payable by or at the
                  direction of the Company as soon as reasonably practicable following the Effective Time, upon receipt of any documents as may reasonably be required by the Warrant Agent, in the amount of $1.60.

        

        
          

          

          ****

        

        
          Warrant Certificate

        

        
          

          

        

        
          This Warrant Certificate certifies that                    , or registered assigns, is the
              registered holder of warrant(s) evidenced hereby (the “Warrants” and each, a “Warrant”) to purchase shares of Class A common stock, $0.0001 par value per share (“Common Stock”), of Trinity Merger Corp., a Delaware corporation (the “Company”). Each Warrant entitles the holder, upon exercise during the period set forth in the Warrant Agreement referred to below, to receive from the Company that number of fully paid and
              non-assessable shares of Common Stock as set forth below, at the exercise price (the “Exercise Price”) as determined pursuant to the Warrant Agreement, payable in lawful money (or through “cashless exercise” as provided for in the Warrant Agreement) of the
              United States of America upon surrender of this Warrant Certificate and payment of the Exercise Price at the office or agency of the Warrant Agent referred to below, subject to the conditions set forth herein and in the Warrant Agreement.
              Defined terms used in this Warrant Certificate but not defined herein shall have the meanings given to them in the Warrant Agreement.

        

        
          

          

        

        
          Each Public Warrant
            is initially exercisable for one-quarter of one
            fully paid and non-assessable share of Common Stock.  The Exercise Price per share of Common Stock for any Public Warrant is equal to $2.875 per one-quarter share ($11.50 per whole share); provided however, that a Public Warrant may not be exercised for a fractional share, so that only a
                multiple of four Public Warrants may be exercised at a given time.

          

          

          Each Private Warrant is exercisable for one fully paid and non-assessable share of Common
              Stock.  The Exercise Price per share of Common Stock for any Private Warrant is equal to $11.50 per share.

          

          

        

        
          No fractional shares will be issued upon exercise of any Warrant.  If, upon the exercise of Warrants, a holder would be entitled to receive a
            fractional interest in a share of Common Stock, the Company will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to the Warrant holder. The number of shares of Common
            Stock issuable upon exercise of the Warrants is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

        

        
           

            

        

        
          The initial Exercise Price per share of Common Stock for any Warrant is equal to $11.50 per share.
                The Exercise Price is subject to adjustment upon the occurrence of certain events set forth in the Warrant Agreement.

        

        
          

          

        

        
          Subject to the conditions set forth in the Warrant Agreement, the Warrants may be exercised only during the Exercise Period and to the extent not
            exercised by the end of such Exercise Period, such Warrants shall become void.

        

        
          

          

        

        
          Reference is hereby made to the further provisions of this Warrant Certificate set forth on the reverse hereof and such further provisions shall for
            all purposes have the same effect as though fully set forth at this place.

        

        
          

          

        

        This Warrant Certificate shall not be valid unless countersigned by the Warrant Agent, as such term is used in the Warrant Agreement.Exhibit 10.1

 

Confidential

 

EMPLOYMENT AGREEMENT

 

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT
(this “Agreement”) is made and entered into as of August 20, 2019 (the “Effective Date”),
by and between uniQure, Inc., 113 Hartwell Avenue, Lexington, MA 02421 (together with any and all of its affiliates, the “Company”)
and Alex Kuta of 293 Willis Road, Sudbury, MA 01776 (the “Executive”).

 

WITNESSETH:

 

WHEREAS, the Company has employed Executive
as Senior Vice President, Regulatory Affairs pursuant to an Employment Agreement dated January 23, 2017 (the “Prior Employment
Agreement”), and now wishes to employ executive as its Executive Vice President, Operations pursuant to a new Employment
Agreement.

 

WHEREAS, Executive wishes to be employed
by the Company in that role and to serve in such capacity under the terms and conditions set forth in this Agreement.

 

WHEREAS, the Company and Executive desire
to terminate the Prior Employment Agreement and contemporaneously replace the Prior Employment Agreement with this Agreement without
out any overlap, gap or discontinuity in the employment of the Executive.

 

NOW, THEREFORE, in consideration of the
mutual promises and covenants contained herein and intending to be legally bound hereby, the Company and Executive agree as follows.

 

1.                 
Employment. The Company hereby agrees to continue to employ Executive, and Executive hereby accepts such continued
employment by the Company, as a full-time employee for the period and upon the terms and conditions contained in this Agreement.
The Prior Employment Agreement is hereby terminated as of the Effective Date.

 

2.                 
Term. Executive’s term of employment with the Company under this Agreement shall begin on the Effective Date,
and shall continue in force and effect from year to year unless terminated earlier in accordance with Section 19 (the “Term”).

 

3.                 
Position and Duties. During the Term, Executive shall serve the Company as its Executive Vice President, Operations,
reporting directly to the uniQure Chief Executive Officer (the “CEO”). Executive’s duties will include
but not be limited to:

 

		§	Designing and implementing uniQure’s global GMP-manufacturing,
quality and regulatory programs and strategies;
		§	Managing pharmaceutical product manufacture according to Food and Drug Administration (FDA) guidelines,
Good Manufacturing Practices (GMP) requirements for clinical trials of Investigational New Drugs (IND) and approved New Drug Applications
(NDA) materials;
		§	Overseeing optimization of existing products manufacturing; assuring compliance with GMP regulations;
		§	Supporting the development of CMC regulatory filings related to the Lexington Manufacturing facility;

 

    	 	Page 1	Initials  AK  

	 	 	 

    Confidential

    

 

		§	Timely and compliant execution of the related activities in the relevant areas and identification
of opportunities for continuous improvement, including compliance with both GMP regulations, as well as environmental and safety
regulations;
		§	Managing the technology transfer process between the Amsterdam and Lexington facilities;
		§	Managing capital investment and maintenance activities related to manufacturing, utilities and
equipment;
		§	Establishing site Quality requirements and directs ongoing development and operations of the
Quality Unit, the compliance function and the GxP Quality Management System globally;
		§	Ensuring company-wide compliance with applicable Quality regulations;
		§	Supervising the development and presentation of periodic reports describing uniQure’s compliance
trends and identifying areas of potential risk;
		§	Directing the Quality oversight of GLP/GCP/GVP and bio-analytical activities (including internal
or external audit observations and development of adverse trends) to ensure patient safety and data integrity;
		§	Working closely and collaboratively with Program Management in the execution of R&D stage-gates;
		§	Overseeing the development and submission of regulatory dossiers globally and lead the preparation
of effective and persuasive presentations and submissions to regulatory authorities and accountable for regulatory inspections
and compliance audits;
		§	Ensuring successful negotiation strategies and execution of interactions with regulatory agencies
in the U.S., Europe and elsewhere, notably with global regulatory agencies;
		§	Reviewing and endorsing key development documents;
		§	Proposing Regulatory consultancies/advisory boards based on clear objectives and supports the
conduct of such processes;
		§	Participating in leadership team meetings, Board meetings and other key operating mechanisms
required of senior management and by the Chief Executive Officer;
		§	Developing budgets for relevant functional responsibilities, subject to approval by the Chief
Executive Officer and Chief Accounting Officer, and ensure execution within approved targets;
		§	Fostering and developing an innovative and productive organization of talented employees, including
the management, motivation, recruitment and evaluation of personnel;
		§	Defining, implementing, maintaining and continually improving processes and systems, supported
by meaningful Key Performance Indicators (KPI’s);
		§	Interacting with staff of other disciplines, such as Finance, Research & Product Development,
Human Resources, Legal, Business Development, Investor Relations and Clinical Development to ensure efficient day-to-day cooperation
and success for the business; and
		§	Performing other duties as may from time to time be assigned by the Company and which are commensurate
with senior executive status.

 

A comprehensive job description is being provided.

 

    	 	Page 2	Initials  AK  

	 	 	 

    Confidential

    

 

4.                 
During the Term, Executive shall devote full business time, best efforts, skill, knowledge, attention and energies to the
advancement of the Company’s business and interests and to the performance of Executive’s duties and responsibilities
as an employee of the Company. Executive shall abide by the rules, regulations, instructions, personnel practices and policies
of the Company and any changes therein that may be adopted from time to time by the Company.

 

5.                 
During the Term, Executive shall not be engaged in any business activity which, in the
judgment of the Company, conflicts with Executive’s duties hereunder, whether or not such activity is pursued for pecuniary
advantage. Should Executive wish to provide any services to any other person or entity other than the Company or to serve on the
board of directors of any other entity or organization, Executive shall submit a written request to the Company for consideration
and approval by the Company, which approval shall not unreasonably be withheld. If the Company later makes a reasonable, good faith
determination that Executive’s continued service on another entity’s board would be detrimental to the Company, it
will give Executive thirty (30) days’ written notice that it is revoking the original approval, and Executive will resign
from the applicable board within thirty (30) days after receipt of such notice.

 

6.                 
Location. Executive shall perform the services hereunder from the Company’s USA
headquarters at 113 Hartwell Avenue, Lexington MA, USA; provided, however, that Executive shall be required to travel from time
to time for business purposes, including, without limitation, to the Company’s facilities in Amsterdam, Netherlands.

 

7.                 
Compensation and Benefits.

 

		(a)	Base Salary. For all services rendered by Executive
under this Agreement, the Company will pay him a base salary at the annual rate of Four Hundred Twenty Nine Thousand Six Hundred
Forty Six Dollars (US $ 429,646), which shall be reviewed annually by the CEO for adjustment (the base salary in effect at any
time, the “Base Salary”). Executive’s Base Salary shall be paid in bi-weekly installments, less withholdings
as required by law and deductions authorized by Executive, and payable pursuant to the Company’s regular payroll practices
in effect at the time and as may be changed from time to time.

 

		(b)	Discretionary Bonus. Following the end of each
calendar year and subject to the approval of the Company, Executive shall be eligible for a target retention and performance bonus
of up to forty percent (40%) of the annual Base Salary based on performance and the Company’s performance and financial
condition during the applicable calendar year, as determined by the Company in its sole discretion (a “Bonus”).
In any event, Executive must be an active employee of the Company on the 1st of October of the relevant calendar year and on the
date the Bonus is distributed in order to be eligible for and to earn any Bonus, as it also serves as an incentive to remain employed
by the Company.

 

    	 	Page 3	Initials  AK  

	 	 	 

    Confidential

    

 

8.                 
Equity. Subject to Board of Directors approval at the next regularly scheduled
uniQure N.V. Board meeting after execution of this Agreement, Executive shall be granted 15,000 (fifteen thousand) Restricted Stock
Units of the Company, the terms of which shall reflect the standard three-year vesting and other terms and conditions contained
in the uniQure N.V.'s Amended and Restated 2014 Share Incentive Plan. Such option will be approved
by the Board of Directors of uniQure N.V. not later than at its next regularly scheduled meeting. If the Board fails to make the
grant at such regularly scheduled meeting, it shall be deemed a Good Reason event under Section 19(f) hereof. The Executive will
be eligible for future equity grants pursuant to the Company's policies and procedures.

 

9.                 
Retirement and Welfare Benefits. Executive is eligible to participate in any and all benefit programs that the Company
establishes and makes available to its employees from time to time, provided that Executive is eligible under (and subject to all
provisions of) the plan documents that govern those programs. These include medical, dental and disability insurances. Benefits
are subject to change at any time in the Company’s sole discretion.

 

10.             
Paid Time Off and Holidays. Executive is eligible for a (pro-rated) maximum of 4 weeks of paid vacation per calendar
year to be taken at such times as may be approved in advance by the Company. Executive is also entitled to all paid holidays observed
by the Company in the United States. Executive shall have all rights and be subject to all obligations and responsibilities with
respect to paid time off and holidays as are set forth in the Company’s employee manual or other applicable policies and
procedures.

 

11.             
Expense Reimbursement. During the Term, Executive shall be reimbursed by the Company for all necessary and reasonable
expenses incurred by Executive in connection with the performance of Executive’s duties hereunder (including business trips
to the uniQure Amsterdam headquarters). Executive shall keep an itemized account of such expenses, together with vouchers and/or
receipts verifying the same, and submit for reimbursement on a monthly basis. Any such expense reimbursement will be made in accordance
with the Company’s travel and expense policies governing reimbursement of expenses as are in effect from time to time.

 

12.             
Withholding. All amounts set forth in this Agreement are on a gross, pre-tax basis and shall be subject to all applicable
federal, state, local and foreign withholding, payroll and other taxes, and the Company may withhold from any amounts payable to
Executive (including any amounts payable pursuant to this Agreement) in order to comply with such withholding obligations.

 

13.             
IP and Restrictive Covenants. The Company’s agreement to enter into this Agreement is contingent upon Executive’s
execution of the Company’s Confidentiality, Developments, and Restrictive Covenants Agreement, attached as Exhibit A
to this Agreement. Nothing in this Agreement or the Confidentiality, Developments, and Restrictive Covenants Agreement shall
prohibit or restrict Executive from initiating communications directly with, responding to any inquiry from, providing testimony
before, providing confidential information to, reporting possible violations of law or regulation to, or filing a claim or assisting
with an investigation directly with a self-regulatory authority or a government agency or entity, including the Equal Employment
Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities
and Exchange Commission, Congress, any agency Inspector General or any other federal, state or local regulatory authority (collectively,
the “Regulators”), or from making other disclosures that are protected under the whistleblower provisions of
state or federal law or regulation. Executive does not need the prior authorization of the Company to engage in conduct protected
by this subsection, and Executive does not need to notify the Company that Executive has engaged in such conduct. Please take
notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to
individuals who disclose trade secrets to their attorneys, courts, or government officials in certain, confidential circumstances
that are set forth at 18 U.S.C. §§ 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected
violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.

 

    	 	Page 4	Initials  AK  

	 	 	 

    Confidential

    

 

14.             
At-Will Employment. This Agreement shall not be construed as an agreement, either express or implied, to employ Executive
for any stated term, and shall in no way alter the Company’s policy of employment at-will, under which both the Company and
Executive remain free to end the employment relationship for any reason, at any time, with or without Cause or notice. Similarly,
nothing in this Agreement shall be construed as an agreement, either express or implied, to pay Executive any compensation or grant
Executive any benefit beyond the end of employment with the Company.

 

15.             
Conflicting Agreements. Executive acknowledges and represents that by executing this Agreement and performing Executive’s
obligations under it, Executive will not breach or be in conflict with any other agreement to which Executive is a party or is
bound, and that Executive is not subject to any covenants against competition or similar covenants that would affect the performance
of Executive’s obligations for the Company.

 

16.             
No Prior Representations. This Agreement and its exhibits constitute all the terms of Executive’s hire and
supersedes all prior representations or understandings, whether written or oral, relating to the terms and conditions of Executive’s
employment.

 

17.              
Change of Control. In the event of a Change of Control as defined below, the vesting conditions that may apply to
any options, restricted shares, restricted stock units, performance stock units or other grants of equity held by Executive pursuant
to this Agreement and the Company’s Amended and Restated 2014 Share Incentive Plan will be automatically waived, and all
the Stock Options will be deemed to be fully exercisable commencing on the date of the Change of Control and ending on the eighteen
(18) month anniversary of the Change of Control or, if earlier, the expiration of the term of such Stock Options. For purposes
of this Agreement, “Change of Control” shall mean the date on which any of the following events occurs:

 

		(a)	any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended
(the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity
holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all “affiliates”
and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial
owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing
forty (40) percent or more of the combined voting power of the Company’s then outstanding securities having the right to
vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition
of securities directly from the Company); or

 

    	 	Page 5	Initials  AK  

	 	 	 

    Confidential

    

 

		(b)	a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is
not endorsed by a majority of the members of the Board before the date of the appointment or election; or

 

		(c)	the consummation of (i) any consolidation or merger of the Company where the stockholders of the Company, immediately prior
to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined
in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than fifty (50) percent of the
voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation,
if any), or (ii) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party
as a single plan) of all or substantially all of the assets of the Company.

 

18.             
RESERVED.

 

19.              
Termination. The Term shall continue until the termination of Executive’s employment with the Company as provided
below.

 

		(a)	Events of Termination. Executive’s employment, Base Salary and any and all other rights of Executive under this
Agreement or otherwise as an employee of the Company will terminate:

 

		(i)	upon the death of Executive;

 

		(ii)	upon the Disability of Executive (immediately upon notice from either party to the other). For purposes hereof, the term “Disability”
shall mean an incapacity by accident, illness or other circumstances which renders Executive mentally or physically incapable of
performing the duties and services required of Executive hereunder on a full-time basis for a period of at least 120 consecutive
days.

 

		(iii)	upon termination of Executive for Cause;

 

		(iv)	upon the resignation of employment by Executive without Good Reason (upon sixty (60) days’ prior written notice);

 

		(v)	upon termination by the Company for any reason other than those set forth in Sections 19(a)(i) through 19(a)(iv) above;

 

		(vi)	upon voluntary resignation of employment by Executive for Good Reason as described in Section 19(f), below;

 

		(vii)	upon a Change of Control Termination as described in Section 19(g), below.

 

    	 	Page 6	Initials  AK  

	 	 	 

    Confidential

    

 

		(b)	In the event Executive’s termination occurs pursuant to Sections 19(a)(i) - (iv) above, Executive will be entitled only
to the Accrued Benefits through the termination date. The Company will have no further obligation to pay any compensation of any
kind (including, without limitation, any Bonus or portion of a Bonus that otherwise may have become due and payable to Executive
with respect to the year in which such termination date occurs), or severance payment of any kind, unless otherwise provided herein.
For purposes of this Agreement, Accrued Benefits shall mean (i) payment of Base Salary through the termination date, (ii) payment
of any Bonus for performance periods completed prior to the termination date, (iii) any payments or benefits under the Company’s
benefit plans that are vested, earned or accrued prior to the termination date (including, without limitation, earned but unused
vacation); and (iv) payment of unreimbursed business expenses incurred by Executive.

 

		(c)	For purposes of this Agreement, “Cause” shall mean the good faith determination by the Company (which determination
shall be conclusive), after written notice from the Company to Executive that one or more of the following events has occurred
and stating with reasonable specificity the actions that constitute Cause and the specific reasonable cure (related to subsections
(i) and (viii) below):

 

		(i)	Executive has willfully or repeatedly failed to perform Executive’s material duties and
such failure has not been cured after a period of thirty (30) days’ written notice;

 

		(ii)	any reckless or grossly negligent act by Executive having the foreseeable effect of injuring the interest, business or reputation
of the Company, or any of its parents, subsidiaries or affiliates in any material respect;

 

		(iii)	Executive’s evidenced use of any illegal drug, or illegal narcotic, or excessive amounts of alcohol (as determined by
the Company in its reasonable discretion) on Company property or at a function where Executive is working on behalf of the Company;

 

		(iv)	the indictment on charges or conviction for (or the procedural equivalent of conviction for), or entering of a guilty plea
or plea of no contest with respect to a felony;

 

		(v)	the conviction for (or the procedural equivalent of conviction for), or entering of a guilty plea or plea of no contest with
respect to a misdemeanor which, in the Company’s reasonable judgment, involves moral turpitude deceit, dishonesty or fraud;
except that, in the event that Executive is indicted on charges for a misdemeanor set forth in this subsection 19(c)(v), the Company
may elect, in its sole discretion, to place Executive on administrative garden leave with or without continuation of full compensation
and benefits under this Agreement during the pendency of the proceedings;

 

    	 	Page 7	Initials  AK  

	 	 	 

    Confidential

    

 

		(vi)	conduct by or at the direction of Executive constituting misappropriation or embezzlement of the property of the Company, or
any of its parents or affiliates (other than the occasional, customary and de minimis use of Company property for personal
purposes);

 

		(vii)	a breach by Executive of a fiduciary duty owing to the Company, including the misappropriation of (or attempted misappropriation
of) a corporate opportunity or undisclosed self-dealing;

 

		(viii)	a material breach by Executive of any material provision of this Agreement, any of the Company’s written employment policies
or Executive’s fiduciary duties to the Company, which breach, if curable, remains uncured for a period of thirty (30) days
after receipt by Executive of written notice of such breach from the Company, which notice shall contain a reasonably specific
description of such breach and the specific reasonable cure requested by the Supervisory Board; and

 

		(ix)	any breach of Executive’s Confidentiality, Developments, and Restrictive Covenants Agreement.

 

		(d)	The definition of Cause set forth in this Agreement shall govern for purposes of Executive’s equity compensation and
any other compensation containing such a concept.

 

		(e)	Notice Period for Termination Under Section 19(a)(iv). Upon a termination of Executive under Section 19(a)(iv), during
the notice period the Company may, in its sole discretion, relieve Executive of all of Executive’s duties, responsibilities,
and authority, may restrict Executive’s access to Company property, and may take other appropriate measures deemed necessary
under the circumstances.

 

    	 	Page 8	Initials  AK  

	 	 	 

    Confidential

    

 

		(f)	Termination by Executive for Good Reason. During the Term, Executive may terminate this Agreement at any time upon thirty
(30) days’ written notice to the Company for Good Reason. For purposes of this Agreement, “Good Reason”
shall mean that Executive has complied with the Good Reason Process (hereinafter defined) following the occurrence of any of the
following actions undertaken by the Company without Executive’s express prior written consent: (i) the material diminution
in Executive’s responsibilities, authority and function; (ii) a material reduction in Executive’s Base Salary, provided,
however, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive’s Base Salary which
is pursuant to a salary reduction program affecting the CEO and all or substantially all other senior management employees of the
Company and that does not adversely affect Executive to a greater extent than other similarly situated employees; provided, however
that such reduction may not exceed twenty (20%) percent; (iii) a material change in the geographic location at which Executive
provides services to the Company (i.e., outside a radius of fifty (50) miles from Lexington, Massachusetts); or (iv) a material
breach by the Company of this Agreement or any other material agreement between Executive and the Company concerning the terms
and conditions of Executive’s employment, benefits or Executive’s compensation (each a “Good Reason Condition”).

 

	 	 	“Good Reason Process” shall mean
    that: (i) Executive has reasonably determined in good faith that a Good Reason Condition has occurred; (ii) Executive has
    notified the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence
    of such condition; (iii) Executive has cooperated in good faith with the Company’s efforts, for a period not less than
    thirty (30) days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding
    such efforts, the Good Reason Condition continues to exist; and (v) Executive terminates employment within sixty (60) days
    after the end of the Cure Period. If the Company cures to Executive’s satisfaction (not unreasonably withheld) the Good
    Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 

		(g)	Termination As A Result of a Change Of Control. For purposes of this Agreement, “Change of Control Termination”
shall mean any of the following:

 

		(i)	Any termination by the Company of Executive’s employment, other than for Cause (as defined in Section 19(c), above),
that occurs within twelve (12) months after the Change of Control; or

 

		(ii)	Any resignation by Executive for Good Reason (as defined in Section 19(f), above), that occurs within twelve (12) months after
the Change of Control.

 

		(iii)	For purposes of this Section 19(g), “Change of Control” shall have the same meaning as defined above in Section
17.

 

		(h)	Separation Benefits. Should Executive experience a termination of employment during the Term pursuant to Section 19(a)(v),
(vi) or (vii) above, in addition to the Accrued Benefits Executive shall also be entitled to:

 

    	 	Page 9	Initials  AK  

	 	 	 

    Confidential

    

 

		(i)	Lump Sum Severance Payment:

 

a.      
In the case of a termination of employment during the Term pursuant to Section 19(a)(v) or (vi) above: a lump sum severance
payment equal to 100% of the sum of (A) Executive’s annual Base Salary and (B) Executive’s target Bonus amount pursuant
to Section 7(b) hereof (i.e., 40% of Executive’s annual Base Salary);

 

b.     
In the case of a termination of employment during the Term pursuant to Section 19(a)(vii) above: a lump sum severance payment
equal to 150% of the sum of (A) Executive’s annual Base Salary and (B) Executive’s target Bonus amount pursuant to
Section 7(b) hereof (i.e., 40% of Executive’s annual Base Salary);

 

		(ii)	a Pro-rata Bonus paid at the target bonus amount for the year of termination, as set forth in and subject to Section 7(b);
as used in this Agreement, the term “Pro-rata Bonus” shall mean the product of the formula B x D/365 where B
represents the target Bonus (i.e., 40% of Executive’s annual Base Salary), and D represents the number of days elapsed
in the calendar year through the date of the separation of Executive’s employment from the Company.

 

		(iii)	Provided that Executive and his eligible dependents, if any, are participating in the Company’s group health, dental
and vision plans on the termination date and elect on a timely basis to continue that participation in some or all of the offered
plans through the federal law commonly known as “COBRA,” the Company will pay or reimburse Executive for Executive’s
full COBRA premiums (i.e., employer and employee portion) until the earlier to occur of: (a) the expiration of the COBRA Payment
Term (as defined below), (b) the date Executive becomes eligible to enroll in the health, dental and/or vision plans of another
employer, (c) the date Executive (and/or his eligible dependents, as applicable) is no longer eligible for COBRA coverage,
or (d) the Company in good faith determines that payments under this paragraph would result in a discriminatory health plan
pursuant to the Patient Protection and Affordable Care Act of 2010, as amended, and any guidance or regulations promulgated thereunder
(collectively, “PPACA”). Executive agrees to notify the Company promptly if he becomes eligible to enroll in
the plans of another employer or if he or any of his dependents cease to be eligible to continue participation in the Company’s
plans through COBRA. “COBRA Payment Term” mean (x) in the case of a termination of employment during the Term pursuant
to Section 19(a)(v) or (vi) above, the twelve (12) month anniversary of Executive’s termination date, and (y) in the case
of a termination of employment during the Term pursuant to Section 19(a)(vii) above, the eighteen (18) month anniversary of Executive’s
termination date.

 

    	 	Page 10	Initials  AK  

	 	 	 

    Confidential

    

 

To avoid duplication of severance
payments, any amount paid under this subsection shall be offset against any severance amounts that may be owed by the Company to
Executive pursuant to any of Company’s Change of Control guidelines as may be adopted or amended.

 

20.              
General Release of Claims. Notwithstanding any provision of this agreement, all severance payments and benefits described
in Section 19 of this Agreement (except for payment of the Accrued Benefits) are conditioned upon the execution, delivery to the
Company, and expiration of any applicable revocation period without a notice of revocation having been given by Executive, all
by the 30th day following the termination date of a General Release of Claims by and between Executive (or Executive’s estate)
and the Company in the form attached as Exhibit B to this Agreement. (In the event of Executive’s death or incapacity
due to Disability, the release will be revised for signature accordingly.) Provided any applicable timing requirements set forth
above have been met, the payments and benefits will be paid or provided to Executive as soon as administratively practicable (but
not later than forty-five (45) days) following the date Executive signs and delivers the General Release to the Company and any
applicable revocation period has expired without a notice of revocation having been given. Any severance or termination pay will
be the sole and exclusive remedy, compensation or benefit due to Executive or Executive’s estate upon any termination of
Executive’s employment (without limiting Executive’s tights under any disability, life insurance, or deferred compensation
arrangement in which Executive participates or at the time of such termination of employment or any Option Agreements or any other
equity agreements to which Executive is a party).

 

21.                Certain Company Remedies. Executive acknowledges that Executive’s promised services and covenants are
of a special and unique character, which give them peculiar value, the loss of which cannot be reasonably or adequately compensated
for in an action at law, and that, in the event there is a breach hereof by Executive, the Company will suffer irreparable harm,
the amount of which will be impossible to ascertain. Accordingly, the Company shall be entitled, if it so elects, to institute
and prosecute proceedings in any court of competent jurisdiction, either at law or in equity, to obtain
damages for any breach of this Agreement, or to enjoin Executive from committing any act in breach of this Agreement. The remedies
granted to the Company in this Agreement are cumulative and are in addition to remedies otherwise available to the Company at law
or in equity.

 

22.               
Indemnification.

 

		(a)	The Company agrees that Executive shall be entitled to indemnification to the fullest extent permitted by Delaware law and
under the Company’s articles of incorporation, bylaws and any other corporate-related plan, program or policy. In addition,
for a period of at least three (3) years after Executive’s termination of employment, the Company shall maintain a directors
and officers liability insurance policy under which Executive shall be included as a “Covered Person.”

 

    	 	Page 11	Initials  AK  

	 	 	 

    Confidential

    

 

		(b)	In addition, and for the sake of clarity, the Company hereby specifically agrees that (i) if
Executive is made a party, or is threatened to be made a party, to any “Proceeding” (defined as any threatened
or actual action, suit or proceeding whether civil, criminal, administrative, investigative, appellate or other) by reason of the
fact that (1) Executive is or was an employee, officer, director, agent, consultant or representative of the Company, or (2) is
or was serving at the request of the Company as employee, officer, director, agent, consultant or representative
of another person, or (ii) if any “Claim” (defined as any claim, demand, request, investigation, dispute, controversy,
threat, discovery request or request for testimony or information) is made, or threatened to be made, that arises out of or relates
to Executive’s service in any of the foregoing capacity or to the Company, then Executive shall be indemnified and held harmless
by the Company to the fullest extent permitted by applicable law, against any and all costs, expenses, liabilities and losses (including,
without limitation, attorney’s fees, judgments, interest, expenses of investigation, penalties, fines, taxes or penalties
and amounts paid or to be paid in settlement) incurred or suffered by Executive in connection therewith, except with respect
to any costs, expenses, liabilities or losses (A) that were incurred of suffered as a result of Executive’s willful misconduct,
gross negligence or knowing violation of any written agreement between Executive and the Company, (B) that a court of competent
jurisdiction determines to have resulted from Executive’s knowing and fraudulent acts; provided,
however, that the Company shall provide such indemnification only if (I) notice of any such Proceeding is given promptly to the
Company, by Executive; (II) the Company is permitted to participate in and assume the defense of any such Proceeding; (III) such
cost, expense, liability or loss results from the final judgment of a court of competent jurisdiction or as a result of a settlement
entered into with the prior written consent of the Company; and (IV) in the case of any such Proceeding (or part thereof) initiated
by Executive, such Proceeding (or part thereof) was authorized in advance in writing by the Company. Such indemnification shall
continue even if Executive has ceased to be an employee, officer, director, agent, consultant or representative of the Company
until all applicable statute of limitations have expired, and shall inure to the benefit of Executive’s heirs, executors
and administrators. The Company shall pay directly or advance to Executive all costs and expenses incurred by Executive in connection
with any such Proceeding or Claim (except for Proceedings brought by the Company against Executive for claims other than shareholder
derivative actions) within 30 days after receiving written notice requesting such an advance. Such notice shall include, to the
extent required by applicable law, an undertaking by Executive to repay the amount advanced if Executive was ultimately determined
not to be entitled to indemnification against such costs and expenses

 

23.             
Miscellaneous.

 

		(a)	Right to Offset. The Company may offset any undisputed amounts Executive owes the Company at the time of Executive’s
termination of employment (including any payment of Accrued Benefits or separation pay), except for secured or unsecured loans,
against any amounts the Company owes Executive hereunder, subject in all cases to the requirements of Section 409A of the Code.

 

    	 	Page 12	Initials  AK  

	 	 	 

    Confidential

    

 

		(b)	Cooperation. Executive agrees that, during and after Executive’s employment with the Company, subject to reimbursement
of Executive’s reasonable expenses, Executive will cooperate fully with the Company and its counsel with respect to any matter
(including, without limitation, litigation, investigations, or governmental proceedings) in which Executive was in any way involved
during Executive’s employment with the Company. Executive shall render such cooperation in a timely manner on reasonable
notice from the Company, and at such times and places as reasonably acceptable to Executive and the Company. The Company, following
Executive’s termination of employment, exercises commercially reasonable efforts to schedule and limit its need for Executive’s
cooperation under this paragraph so as not to interfere with Executive’s other personal and professional commitments.

 

		(c)	Company Documents and Property. Upon termination of Executive’s employment with
the Company, or at any other time upon the request of Company, Executive shall forthwith deliver to Company any and all documents,
notes, notebooks, letters, manuals, prints, drawings, block diagrams, photocopies of documents, devices, equipment, keys, security
passes, credit cards, hardware, data, databases, source code, object code, and data or computer programming code stored on an optical
or electronic medium, and any copies thereof, in the possession of or under the control of Executive that embodies any confidential
information of the Company. Executive agrees to refrain from purging or deleting data from any Company-owned
equipment, including email systems, in connection with Executive’s termination. To the extent that Executive possesses any
data belonging to Company on any storage media owned by Executive (for example, a home computer’s hard disk drive, portable
data storage device, etc.), Executive agrees that Executive will work cooperatively with the Company to return such data and ensure
it is removed from Executive’s devices in a manner that does not adversely impact any personal data. Executive agrees not
to take any steps to delete any Company data from any device without first obtaining Company’s written approval. Executive
agrees to cooperate with Company if Company requests written or other positive confirmation of the return or destruction of such
data from any personal storage media. Nothing herein shall be deemed to prohibit Executive from retaining (and making copies of):
Executive’s personal non-business-related correspondence files; or (ii) documents relating to Executive’s personal
compensation, benefits, and obligations.

 

		(d)	Waivers. No waiver of any provision will be effective unless made in writing and signed by the waiving party. The failure
of any party to require the performance of any term or obligation of this Agreement does not prevent subsequent enforcement of
that term or obligation. The waiver by any party of any breach of this Agreement does not waive any subsequent breach.

 

    	 	Page 13	Initials  AK  

	 	 	 

    Confidential

    

 

		(e)	Section 409A. This Agreement is intended to comply with Section 409A of the Code, and its corresponding regulations,
or an exemption thereto, and payments may only be made under this Agreement upon an event and in a manner permitted by Section
409A of the Code, to the extent applicable. Severance benefits under this Agreement are intended to be exempt from Section 409A
of the Code under the “short-term deferral” exception, to the maximum extent applicable, and then under the “separation
pay” exception, to the maximum extent applicable. Notwithstanding anything in this Agreement to the contrary, if required
by Section 409A of the Code, if Executive is considered a “specified employee” for purposes of Section 409A of the
Code and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from
service pursuant to Section 409A of the Code, payment of such amounts shall be delayed as required by Section 409A of the Code,
and the accumulated amounts shall be paid in a lump-sum payment within 10 days after the end of the six-month period. If Executive
dies during the postponement period prior to the payment of benefits, the amounts withheld on account of Section 409A of the Code
shall be paid to the personal representative of Executive’s estate within 60 days after the date of Executive’s death.
All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation from service”
under Section 409A of the Code. For purposes of Section 409A of the Code, each payment hereunder shall be treated as a separate
payment, and the right to a series of installment payments under this Agreement shall be treated as a right to a series of separate
payments. In no event may Executive, directly or indirectly, designate the fiscal year of a payment. Notwithstanding any provision
of this Agreement to the contrary, in no event shall the timing of Executive’s execution of the General Release, directly
or indirectly, result in Executive’s designating the fiscal year of payment of any amounts of deferred compensation subject
to Section 409A of the Code, and if a payment that is subject to execution of the General Release could be made in more than one
taxable year, payment shall be made in the later taxable year. All reimbursements and in-kind benefits provided under this Agreement
shall be made or provided in accordance with the requirements of Section 409A of the Code, including, where applicable, the requirement
that (i) any reimbursement be for expenses incurred during the period specified in this Agreement, (ii) the amount of expenses
eligible for reimbursement, or in-kind benefits provided, during a fiscal year not affect the expenses eligible for reimbursement,
or in-kind benefits to be provided, in any other fiscal year, (iii) the reimbursement of an eligible expense be made no later than
the last day of the fiscal year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind
benefits not be subject to liquidation or exchange for another benefit.

 

    	 	Page 14	Initials  AK  

	 	 	 

    Confidential

    

 

		(f)	Governing Law; Consent to Exclusive Jurisdiction and Venue. This Agreement and all questions relating to its validity,
interpretation, performance and enforcement (including, without limitation, provisions concerning limitations of actions), shall
be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts (notwithstanding any conflict-of-laws
doctrines of such state or other jurisdiction to the contrary), and without the aid of any canon, custom or rule of law requiring
construction against the draftsman. The parties hereby consent and submit to the exclusive jurisdiction of the federal and state
courts in the Commonwealth of Massachusetts, and to exclusive venue in any Massachusetts federal court and/or Massachusetts state
court located in Suffolk County, for any dispute arising from this Agreement.

 

		(g)	Notices. Any notices, requests, demands, and other communications described in this Agreement are sufficient if in writing
and delivered in person or sent postage prepaid, by certified or registered U.S. mail or by FedEx/UPS to Executive at Executive’s
last known home address and a copy by e-mail to Executive, or in the case of the Company, to the attention of the CFO or SVP HR,
copy to the CEO at the main office of uniQure, N.V. Any notice sent by U.S. mail shall be deemed given for all purposes 72 hours
from its deposit in the U.S. mail, or the next day if sent by overnight delivery.

 

		(h)	Successors and Assigns. Executive may not assign this Agreement, by operation of law or otherwise, without the Company’s
prior written consent. Without the Company’s consent, any attempted transfer or assignment will be void and of no effect.
The Company may assign its rights under this Agreement if the Company consolidates with or merges into any other entity, or transfers
substantially all of its properties or assets to any other entity, provided that such entity expressly agrees to be bound by the
provisions hereof. This Agreement will inure to the benefit of and be binding upon the Company and Executive, their respective
successors, executors, administrators, heirs, and permitted assigns.

 

		(i)	Counterparts; Facsimile. This Agreement may be executed in two or more counterparts, each of which shall be an original
and all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile transmission,
PDF, electronic signature or other similar electronic means with the same force and effect as if such signature page were an original
thereof.

 

		(j)	Severability. The provisions of this Agreement are independent of and separable from each other, and no provision shall
be affected or rendered invalid or unenforceable by virtue of the fact that for any reason any other provision or provisions may
be invalid or unenforceable in whole or in part.

 

    	 	Page 15	Initials  AK  

	 	 	 

    Confidential

    

 

		(k)	Enforceability. If any portion or provision of the Agreement is declared illegal or unenforceable by a court of competent
jurisdiction, the remainder of the Agreement will not be affected, and each remaining portion and provision of this Agreement will
be valid and enforceable to the fullest extent permitted by law.

 

		(l)	Survival. Sections 13, 20, 21, and the Company’s Confidentiality, Developments, and Restrictive Covenants Agreement
(Exhibit A) and all other provisions necessary to give effect thereto, shall survive the termination of Executive’s
employment for any reason.

 

		(m)	Recoupment and Other Policies. All payments under this Agreement shall be subject to any applicable clawback and recoupment
policies and other policies that may be implemented by the Board from time to time, including, without limitation, the Company’s
right to recover amounts in the event of a financial restatement due in whole or in part to fraud or misconduct by one or more
of the Company’s executives or in the event Executive violates any applicable restrictive covenants in favor of the Company
to which Executive is subject.

 

		(n)	Entire Agreement; Amendment. This Agreement contains the entire understanding among the parties hereto with respect
to the subject matter hereof, and supersedes all prior and contemporaneous agreements and understandings, inducements or conditions,
express or implied, oral or written, between the parties hereto (including without limitation any prior employment agreements between
the parties hereto); provided, however, that any agreements referenced in this Agreement or executed herewith are not superseded.
The express terms hereof control and supersede any course of performance and/or usage of the trade inconsistent with any of the
terms hereof. This Agreement may be amended or modified only by a written instrument signed by Executive and by a duly authorized
representative of the Company.

 

		(o)	Section Headings. The section headings in this Agreement are for convenience only, form no part of this Agreement and
shall not affect its interpretation.

 

[This space intentionally left blank.]

 

    	 	Page 16	Initials  AK  

	 	 	 

    Confidential

    

 

IN WITNESS WHEREOF, the parties have executed
and delivered this Agreement as of the date first above written.

 

	 	uniQure,
    Inc.
	 	 
	 	By:	/s/ Matthew Kapusta
	 	 	Name:
    Matthew Kapusta
	 	 	Title:
    Chief Executive Officer
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Alex
    Kuta
	 	Alex
    Kuta

 

    	 	Page 17	Initials  AK  

	 	 	 

    

    

 

EXHIBIT A

UNIQURE, INC.

CONFIDENTIALITY, DEVELOPMENTS, AND

RESTRICTIVE COVENANTS AGREEMENT

[ attached ]

 

    	Confidentiality, Development and 
Restrictive Covenant Agreement
	Page 18	Employee Initials ____

	 		 

     

    

 

EXHIBIT B

 

GENERAL RELEASE OF CLAIMS

 

In exchange for the promises and benefits
set forth in Section 19 of the Employment Agreement between uniQure, Inc. and Alex Kuta made as of August 20, 2019, and
to be provided to me following the Effective Date of this General Release, I, Alex Kuta, on behalf of myself, my heirs,
executors and assigns, hereby acknowledge, understand and agree as follows:

 

1.       On
behalf of myself and my family, heirs, executors, administrators, personal representatives, agents, employees, assigns, legal representatives,
accountants, affiliates and for any partnerships, corporations, sole proprietorships, or other entities owned or controlled by
me, I fully release, acquit, and forever discharge uniQure, Inc., its past, present and future officers, directors, shareholders,
agents, representatives, insurers, employees, attorneys, subsidiaries, affiliated corporations, parents, and assigns (collectively,
the “Releasees”), from any and all charges, actions, causes of action, claims, grievances, damages, obligations, suits,
agreements, costs, expenses, attorneys’ fees, or any other liability of any kind whatsoever, suspected or unsuspected, known
or unknown, which have or could have arisen out of my employment with or services performed for Releasees and/or termination of
my employment with or termination of my services performed for Releasees (collectively, “Claims”), including:

 

		a.	Claims arising under Title VII of the Civil Rights Act of 1964 (as amended); the Civil Rights Acts
of 1866 and 1991; the Americans With Disabilities Act; the Family and Medical Leave Act; the Employee Retirement Income Security
Act; the Occupational Health and Safety Act; the Sarbanes-Oxley Act; the Massachusetts Law Against Discrimination (M.G.L. c. 151B,
et seq., and/or any other laws of the Commonwealth of Massachusetts related to employment or the separation from employment;

 

		b.	Claims for age discrimination arising under the Age Discrimination in Employment Act of 1967 (as
amended) (“ADEA”) and the Older Workers Benefits Protection Act, except ADEA claims that may arise after the execution
of this General Release;

 

		c.	Claims arising out of any other federal, state, local or municipal statute, law, constitution,
ordinance or regulation; and/or

 

		d.	Any other employment related claim whatsoever, whether in contract, tort or any other legal theory,
arising out of or relating to my employment with the Company and/or my separation of employment from the Releasees.

 

		e.	Excluded from this General Release are any claims that cannot be released or waived by law. This
includes, but is not limited to, my right to file a charge with or participate in an investigation conducted by certain government
agencies, such as the EEOC or NLRB. I acknowledge and agree, however, that I am releasing and waiving my right to any monetary
recovery should any government agency pursue any claims on my behalf that arose prior to the effective date of this General Release.

 

		f.	I waive all rights to re-employment with the Releasees. If I do apply for employment with the Releasees,
the Releasees and I agree that the Releasees need not employ me, and that if the Releasees declines to employ me for any reason,
it shall not be liable to me for any cause of action or damages whatsoever.

 

    	General Release of Claims
		Employee Initials ____

	 	Page 1	 

    Confidential 

    

 

2.       Release
of Other Claims. I fully release, acquit, and forever discharge the Releasees from any and all other charges, actions, causes of
action, claims, grievances, damages, obligations, suits, agreements, costs, expenses, attorneys’ fees or any other liability
of any kind whatsoever of which I have knowledge as of the time I sign this General Release.

 

3.       I
further acknowledge that I have received payment, salary and wages in full for all services rendered in conjunction with my employment
with uniQure, Inc., including payment for all wages, bonuses, and accrued, unused paid time off, and that no other compensation
is owed to me except as provided herein. I specifically understand that this general release of claims includes, without limitation,
a release of claims for alleged wages due, overtime or other compensation or payment including any claim for treble damages, attorneys’
fees and costs pursuant to the Massachusetts Wage Act and State Overtime Law M.G.L. c. 149, §§148, 150 et seq. and
M.G.L. c. 151, §IA et seq. and I further acknowledge that I are unaware of any facts that would support a claim against
the Released Parties for violation of the Fair Labor Standards Act or the Massachusetts Wage Act.

 

4.       Notwithstanding
anything to the contrary herein, nothing in this General Release shall be deemed to release any of the Releasees for: (i) any claim
for the payment of compensation due under the Employment Agreement; (ii) any claim for any of the Accrued Benefits under the Employment
Agreement; (iii) any claim for any separation benefit under Section 19 of the Employment Agreement including, without limitation,
separation pay and accelerated vesting of stock options (as applicable and as defined in the Employment Agreement); or (iv) any
rights to indemnification or coverage under a directors and officers liability insurance policy.

 

5.       Restrictive
Covenants. I acknowledge and agree that all of my obligations under the restrictive covenants in my Confidentiality, Developments,
and Restrictive Covenants Agreement remain in full force and effect and shall survive the termination of my employment with the
Releasees and the execution of this General Release.

 

6.       Consultation
with Attorney. I am advised and encouraged to consult with an attorney prior to executing this General Release. I acknowledge that
if I have executed this General Release without consulting an attorney, I have done so knowingly and voluntarily.

 

7.       Period
for Review. I acknowledge that I have been given at least 21 days from the date I first received this General Release (or at least
45 days from the date I first received this General Release if my termination is part of a group reduction in force) during which
to consider signing it.

 

8.       Revocation
of General Release. I acknowledge and agree that I have the right to revoke my acceptance of this General Release if I notify the
Releasees in writing within 7 calendar days following the date I sign it. Any revocation, to be effective, must be in writing,
signed by me, and either: a) postmarked within 7 calendar days of the date I signed it and addressed to the then current address
of uniQure, Inc.’s headquarters (to the attention of the CEO); orb) hand delivered within 7 days of execution of this General
Release to the uniQure, Inc.’s CEO. This General Release will become effective on the 8th day
after I sign it (the “Effective Date”); provided that I have not timely revoked it.

 

    	Confidentiality, Development and 
Restrictive Covenant Agreement
		Employee Initials ____

	 	Page 2	 

    Confidential

    

 

I ACKNOWLEDGE AND AGREE THAT I HAVE BEEN
ADVISED THAT THE GENERAL RELEASE IS A LEGAL DOCUMENT, AND I HAVE BEEN ADVISED TO CONSULT WITH AN ATTORNEY CONCERNING THIS GENERAL
RELEASE. I ACKNOWLEDGE AND AGREE THAT I HAVE CAREFULLY READ AND FULLY UNDERSTAND ALL PROVISIONS OF THIS GENERAL RELEASE AND I AM
VOLUNTARILY AND KNOWINGLY SIGNING IT.

 

IN, WITNESS WHEREOF, I have duly executed
this Agreement under seal as of the ________ [day] of _______ [month],_________
[year]

 

	 	Alex Kuta
	 	293 Willis Road, Sudbury, MA 01776

 

    	Confidentiality, Development and 
Restrictive Covenant Agreement
		Employee Initials ____

	 	Page 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]